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Original Article
Patient's Outcome of Bladder Cancer managed by radical Cystectomy with
lymphadenectomy at a University Hospital
M. Hammad Ather, Anila Jamshaid, Zaheer Alam, Khurrum M Siddique, M. Nasir Sulaiman
Department of Surgery, Aga Khan University, Karachi.
Abstract
Objective: To study the impact of tumour staging and nodal metastases in predicting 5- year's survival after
radical cystectomy and bilateral pelvic lymphadenectomy for primary bladder cancer. 
Methods: During the period 1995 to 2005, 58 patients underwent radical cystectomy and bilateral pelvic
lymphadenectomy and urinary diversion at a University hospital. Patients were identified using medical indexing
coding system (ICD 9CM) using standard key words. The patient records were analyzed and follow up data
updated. Disease specific survival, death or recurrence was taken as end point.
Results: Out of 58 patients, 50 (86%) were males and 8 (14%) females with a mean age of 61 + 13.1 years
(range from 27 to 87 years).Of  58 patients, 11 (23%) were excluded from the study because of in adequate
follow up. The mean follow up was 5.7 years (range, 7 months to 11 years).The overall 5 years survival was 55%
with disease specific survival being 66%. Patients with pathological stage T0 at cystectomy have 87% 5 years
disease specific survival compared to 60%, in patients with pT4 (p=0.705) The 5-year survival for node positive
patients was 16%, compared to 60% for node negative patients (p<0.01)
Conclusions: Radical cystectomy and bilateral pelvic lymphadenectomy is the standard treatment for muscle
invasive and high grade T1 cancers, and as salvage for recurrent cancers. Lymphadenectomy has a potential
therapeutic benefit. The pathological stage at cystectomy and nodal status are predictors of 5 years survival
(JPMA 57:536:2007). 
Introduction
Bladder cancer is the second most common
genitourinary malignancy, with transitional carcinoma
(TCC) comprising nearly 90% of all primary bladder
tumors. It represents a significant worldwide health
problem. In the United States its current prevalence is
approximately 500,000.1 Though majority of newly
diagnosed bladder tumors are superficial cancers,
approximately one forth of patients either present with or
subsequently develop invasive cancers that will require
aggressive management.
Radical cystectomy, along with extended pelvic
lymphadenectomy, is considered as gold standard treatment
for invasive bladder cancer.2 Improved perioperative care
and technique of anaesthesia have reduced the morbidity
and mortality. Furthermore, ability to offer orthotopic
reconstruction has improved the quality of life and patient's
acceptance for the extirpative surgery. 
Radical cystectomy cures half of the patients, while
the remainder suffer from loco-regional and distant
metastasis within 2-3 years. A more aggressive approach is
warranted for some patients. This involves the use of
adjuvant chemotherapy with surgery.3-5
Predicting outcomes (survival and risk of disease
recurrence) after radical cystectomy has been most
commonly based on pathological staging of primary tumour
and regional lymph node status. Several large,
contemporary radical cystectomy series have documented
risks of recurrence and death based on either TNM staging
or pathological groupings that separate organ confined,
extra vesical, or node-positive tumors.6-12
Alternative prognostic models capable of
simultaneous evaluation of multiple relevant variables have
been shown to provide improved estimates of outcome that
more accurately can be applied to an individual patient.13,14
Providing accurate estimate for the risk of disease
progression after radical cystectomy is critical for improved
patient/clinician decision making with regards to the need
of adjuvant therapy. In addition, accurate prognostic tools
will enhance the ability to interpret and compare clinical
trials of bladder cancer treatments by assigning risk
estimate for the patient populations studied.
The current work is conducted to study the impact of
tumour staging and nodal metastasis as the predictors of 5-
year survival following radical cystectomy and bilateral
pelvic lymphadenectomy in patients at a university hospital.
Patients and Methods
Between the year 1995 and 2005, 58 patients
underwent radical cystectomy for primary carcinoma of
bladder. Bladder cancer was diagnosed by cystoscopy and
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transurethral resection of bladder tumour was done.
Preoperative staging work-up involved complete history
and physical examination, complete laboratory work-up,
chest radiography, CT scan, MRI or ultrasound of abdomen
and pelvis. Radio isotopic bone scan was done for patients
in whom the clinical symptoms or laboratory finding
suggested bone metastases.
Indications of radical cystectomy were based on
clinical and pathological staging of the disease. This
included muscle invasive bladder cancer, high grade
tumour, high volume superficial cancer, invasive tumor
refractory to radiotherapy and/or systemic chemotherapy, or
highly recurrent superficial cancer following endoscopic
resection and intra vesical treatment. 
All patients underwent bilateral pelvic
lymphadenectomy with radical cystectomy and urinary
diversion. Concomitant urethrectomy was performed only
in patient, with concomitant urethral cancer or bladder caner
involving bladder neck and prostatic urethra. The tumors
were staged according to TNM 1997 classification. 
Following cystectomy, patients were initially seen
one month after surgery and then after every 3 months for 1
year and every 6 months until disease progression or death.
Patients  were followed-up by complete physical
examination, complete renal profile and blood picture and
electrolytes, chest X-ray, CT abdomen and pelvis and
radioisotope bone scan whenever indicated.
Survival estimate were constructed using the
Kaplan-Meier product limit methods. The variables
evaluated were, age gender, tumour cell type, pathological
stage and nodal involvement.
Results
The mean patient's age was 61 + 13.1 (range 28-87
years) for 50 (86%) men and 8 (14%) women. Follow up
ranged from 7 months to 11 years (mean 5.7 years). All
patients were subjected to cystectomy, bilateral pelvic
lymphadenectomy and urinary diversion in the form of ileal
conduit in 43 (74%) patients, orthotopic ileal neo bladder
replacement in 12 (21%) patients, Mainz 2 pouch (modified
uretero-sigmoidostomy) in 1 (2%) patients, Indiana pouch
(cutaneous continent diversion) in 2 (3%) patients.
Histopathologically, TCC was the most common
tumour cell type diagnosed in 55 (95%) patients, followed by
squamous cell carcinoma in 2 (3%) patients and
adenocarcinoma in 1 (2%) patient. The pathological tumour
stage at cystectomy was pT0 in 10 (17%) patients, pT1 in 3
(5%) patients, pT2 in 21 (36%) patients, pT3 in 7 (12%)
patients, pT4 in 14 (24%) patients, adenocarcinoma in 1
(2%), and squamous cell carcinoma in 2 (3%) patients.
Out of 58 patients 5 (9%) had preoperative
radiotherapy and systemic chemotherapy and 2 (3%)
received only systemic chemotherapy. Out of 5 patients, who
received both systemic chemotherapy and radiotherapy, 1
(20%) belonged to pT1 group; and 2 patients receiving only
systemic chemotherapy belonged to pT0 group. The most
common systemic chemotherapy given was MVAC (3
patients), Cisplastin was given to 2 patients, and 2 patients
received TAXOl. Fourteen (24%) patients received intra
vesical chemo or immuno-therapy. Mitomycin was given to
10 patients while 4 patients received intravesical BCG.  Out
of 58 patients, 11 (23%) were excluded from study due to
inadequate follow up. 
Kaplan Meier estimate of the 5-year disease free
survival for the entire group was 66 % (Figure).  Survival was
directly related to final pathological stage and as the tumor
stage progressed from superficial bladder cancer through
pT4, survival significantly decreased (p= 0.71). In pT0 the 5
year survival was 87%, 33 % in pT1, 44 % in pT2, 40% in
pT3, and 60% in pT4. The 5-year survival dropped sharply
from 60% in node negative to 16 % in node positive patient
(p<0.01). The  recurrence rate for pT0 was 0%, 33% for
pT1,4% for pT2,60%for pT3, 20% for pT4,0% for patient
with sqamous cell carcinoma and adenocarcinoma(p=0.450).
The recurrence increase sharply from 19 % in node negative
to 33 % in node positive patients (p<0.138). 
Discussion
Radical cystectomy and bilateral lymphadenectomy
is a standard treatment for muscle invasive bladder cancer.
It effectively removes the primary tumour and the regional
lymph nodes that contain metastases in about 25% of
patients undergoing this procedure.15-17 However, even if
muscle invasive bladder cancer was shown to be organ
confined at radical cystectomy, up to half of patients
ultimately die of disease in spite of apparently complete
surgical removal.
Figure. The 5-year survival. Kaplan-Myer survival curve.
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In the current work pathological staging and lymph
node status were the main prognostic factors that influenced
the survival and recurrence of disease. But the results
relating to the tumour staging were not significant. 
Over all survival of patients was 66%, which is
comparable with most published reports.17-19 The final
pathological stage of tumour is a powerful prognostic
indicator after radical cystectomy.15,17 In pT0, the overall
survival was 87%; 60% of the patients in the pT3 group had
metastases at a mean follow up of 5.7 years.
Pelvic lymph node involvement has been
demonstrated to be a highly ominous factor in most reported
contemporary series.19-24 The reported incidence of regional
involvement varied between 14 and 27% and this correlated
with the pathologic stage of the primary tumors. In the
present series, 12% of the patients had metastatic lymph
node involvement. Survival in lymph node negative group
was 60% while it was only 16% in the lymph node positive
group. Recurrence in lymph node positive group was 33%
while in lymph node negative group was 19%.
Early detection, proper patient selection and
improved surgical techniques all have been reported to
significantly decrease the chance of local pelvic recurrence
following radical cystectomy.  In the recent years most
contemporary series with extended lymph node dissection
reports an average of 10 % local recurrence (range, 4% to
8%).25
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